




RealRate

PHARMACEUTICAL 2018

Syros Pharmaceuticals Inc.
Rank 239 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Syros Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syros Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 191% points. The greatest weakness of Syros Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 207% points.

The company's Economic Capital Ratio, given in the ranking table, is -323%, being 45% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	73,159
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,413
Liabilities, Non-Current	0
Other Assets	1,391
Other Compr. Net Income	-33
Other Expenses	0
Other Liabilities	0
Other Net Income	1,777
Property and Equipment	3,938
Research and Development	41,896
Revenues	0
Selling, General and Administrative Expense	13,891

Output Variable	Value in 1000 USD
Assets	78,488
Liabilities	12,413
Expenses	55,787
Stockholders Equity	66,075
Net Income	-54,010
Comprehensive Net Income	-54,026
Economic Capital Ratio	-323%